Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesActive in the last 2 years

Gang Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0595-8237; OpenAlex author ID A5100438753. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
66
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 5 papers · 2022: 3 papers · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 17

  1. Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. Co-author DOI 10.1038/s41467-025-57520-3↗
  2. Risk factors of positive resection margin differ in pancreaticoduodenectomy and distal pancreatosplenectomy for pancreatic ductal adenocarcinoma undergoing upf… Co-author DOI 10.1016/j.asjsur.2022.09.156↗
  3. Clinical characteristics, treatment patterns and survival outcomes of early-onset pancreatic adenocarcinoma: a population-based study. Co-author PMID 36777821↗
  4. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases. Co-author DOI 10.1016/j.ijsu.2022.106786↗
  5. LINC00483 promotes proliferation and metastasis through the miR-19a-3p/TBK1/MAPK axis in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.21037/atm-22-907↗
  6. Folate receptor-positive circulating tumor cells predict survival and recurrence patterns in patients undergoing resection for pancreatic cancer. Co-author DOI 10.3389/fonc.2022.1012609↗
  7. Which Factors Are Associated with Positive Resection Margin in Pancreatic Ductal Adenocarcinoma for different surgical procedures? Results Based on a Standard … Co-author DOI 10.21203/rs.3.rs-111309/v2↗
  8. Risk Factors of Positive Resection Margin Differ in Pancreaticoduodenectomy and Distal Pancreatosplenectomy For Pancreatic Ductal Adenocarcinoma: A Study Based… Co-author DOI 10.21203/rs.3.rs-963631/v1↗
  9. Hepatic Artery Infusion of Floxuridine in Combination With Systemic Chemotherapy for Pancreatic Cancer Liver Metastasis: A Propensity Score-Matched Analysis in… Co-author DOI 10.3389/fonc.2021.652426↗
  10. The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients. Co-author DOI 10.3389/fonc.2021.717989↗
  11. Transcriptome profiling reveals liver metastasis-associated genes in pancreatic ductal adenocarcinoma. Last author DOI 10.3934/mbe.2021088↗
  12. Radical antegrade modular pancreatosplenectomy versus standard distal pancreatosplenectomy for pancreatic cancer, a dual-institutional analysis. Co-author DOI 10.21037/cco-20-6↗
  13. Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice. Co-author DOI 10.1371/journal.pone.0184455↗
  14. MiR-200a Suppresses the Proliferation and Metastasis in Pancreatic Ductal Adenocarcinoma through Downregulation of DEK Gene. Last author DOI 10.1016/j.tranon.2015.11.005↗
  15. MiR-940 inhibited pancreatic ductal adenocarcinoma growth by targeting MyD88. Co-author DOI 10.1159/000373941↗
  16. miR-429 determines poor outcome and inhibits pancreatic ductal adenocarcinoma growth by targeting TBK1. Co-author DOI 10.1159/000373995↗
  17. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Co-author DOI 10.1016/j.surg.2011.07.006↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gang Jin · 9 shared papers, 2015–2025 · strength 1.08
  2. Suizhi Gao · 6 shared papers, 2021–2025 · strength 0.82
  3. Xiaohan Shi · 5 shared papers, 2021–2025 · strength 0.64
  4. Kailian Zheng · 5 shared papers, 2015–2025 · strength 0.63
  5. Chenming Ni · 4 shared papers, 2021–2023 · strength 0.62
  6. Shiwei Guo · 5 shared papers, 2020–2025 · strength 0.60
  7. Xiaoyi Yin · 4 shared papers, 2021–2025 · strength 0.59
  8. Hui Jiang · 3 shared papers, 2021–2023 · strength 0.43
  9. Wan Yee Lau · 3 shared papers, 2021–2023 · strength 0.43
  10. Guoxiao Zhang · 3 shared papers, 2021–2025 · strength 0.39
  11. Wei Jing · 3 shared papers, 2020–2025 · strength 0.35
  12. Bo Li · 2 shared papers, 2021–2023 · strength 0.31
  13. Bin Song · 3 shared papers, 2015–2025 · strength 0.28
  14. Xiongfei Xu · 2 shared papers, 2021–2025 · strength 0.26
  15. Shuo Shen · 2 shared papers, 2021–2022 · strength 0.23
  16. Xiangui Hu · 2 shared papers, 2020–2022 · strength 0.21
  17. Tianlin He · 2 shared papers, 2020–2022 · strength 0.21
  18. Wenyu Liu · 1 shared paper, 2022 · strength 0.19
  19. Siqian Ren · 1 shared paper, 2023 · strength 0.18
  20. Chunhui Yuan · 1 shared paper, 2023 · strength 0.18
  21. Qing Chen · 1 shared paper, 2023 · strength 0.18
  22. Chen Ye · 1 shared paper, 2023 · strength 0.18
  23. Yang Yu · 1 shared paper, 2021 · strength 0.17
  24. Chunming Zhang · 1 shared paper, 2025 · strength 0.16
  25. Yunguang Li · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.